Drug Type Fusion protein |
Synonyms PD-L1 checkpoint inhibitor/mutant IL-15(Jiangsu Simcere Pharmaceutical), human IL-15-IL-15 receptor alpha sushi complex/anti-PD-L1 antibody fusion(Jiangsu Simcere Pharmaceutical) |
Target |
Action agonists, inhibitors |
Mechanism IL-15Rα agonists(Interleukin-15 receptor subunit alpha agonists), PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | - |